Denali Advisors LLC Exelixis, Inc. Transaction History
Denali Advisors LLC
- $929 Million
- Q4 2024
A detailed history of Denali Advisors LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Denali Advisors LLC holds 12,631 shares of EXEL stock, worth $442,085. This represents 0.05% of its overall portfolio holdings.
Number of Shares
12,631
Previous 8,431
49.82%
Holding current value
$442,085
Previous $218,000
92.66%
% of portfolio
0.05%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding EXEL
# of Institutions
569Shares Held
249MCall Options Held
1.72MPut Options Held
1.54M-
Black Rock Inc. New York, NY33.5MShares$1.17 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.4MShares$1.03 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA23.4MShares$820 Million4.16% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.3MShares$535 Million0.8% of portfolio
-
State Street Corp Boston, MA11.4MShares$399 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...